Daiichi Sankyo Company, Limited

4568

JP3475350009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 12:00:00 09/03/2026 pm IST			5-day change	1st Jan Change
2,849.00 ^JPY	-0.63%		-7.02%	-14.90%

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
09/03	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT

Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.

Published on 01/05/2026 at 01:36 pm IST

S&P Capital IQ

DAIICHI SANKYO COMPANY, LIMITED

-0.63%

From October 1, 2025 to December 31, 2025, the company has repurchased 0 shares, representing 0% for ¥0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for ¥0 million under the buyback announced on April 25, 2025.

Latest news about Daiichi Sankyo Company, Limited

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
09/03	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT
09/03	Astra drug wins US review as oil surges above USD100	AN
09/03	AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer	MT
09/03	Daiichi Sankyo says Enhertu gets U.S. Priority Review for HER2-positive early breast cancer	RE
09/03	AstraZeneca and Daiichi secure US fast-track status for cancer drug	AN
09/03	AstraZeneca, Daiichi Sankyo's Enhertu Receives US FDA Priority Review Status in Early Breast Cancer	MT
26/02	Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026	CI
26/02	Daiichi Sankyo Company, Limited Announces Retirement of Sunao Manabe as Representative Director Executive Chairperson, Effective February 26, 2026	CI
24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis	MT
24/02	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
24/02	Daiichi Sankyo Company, Limited Announces Executive Changes Effective from April 1, 2026	CI
23/02	Sylamorebio announces research collaboration with Daiichi Sankyo	RE
23/02	SylamoreBio Announces Research Collaboration with Daiichi Sankyo to Advance SyLEC Delivery Technology	CI

Chart Daiichi Sankyo Company, Limited

Duration

Period

4568: Dynamic Chart

Company Profile

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Employees

19,765

Sector

Pharmaceuticals

Calendar

30/03 - Ex-dividend date - 39 JPY

More about the company